Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00549718 · ClinicalTrials.gov registry record · Phase 3
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 489
- Enrollment target
NCT00549718 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 489 participants.
The verdict
NCT00549718, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 489 participants
- Enrollment target
Study Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
Interventions
- DRUG Lurasidone HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00549718
The ClinicalTrials.gov registry entry for NCT00549718 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 489 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurasidone HCl is the first listed.
NCT00549718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00549718 about?
NCT00549718 is a clinical study titled "Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia". Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
What is the current status of trial NCT00549718?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 489 participants. The study started on 2007-10. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00549718?
The interventions under investigation include: Lurasidone HCl (DRUG).
Who is sponsoring clinical trial NCT00549718?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.